Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Rising Dose Study of TAK-994 in Narcolepsy With or Without Cataplexy
2020-000777-24Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firazorexton in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) (4 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability (Part A and Part D), Pharmacokinetics (Part A and Part D) and 1 more. Started Sep 2020; status: completed.
02
Drugs
firazorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on 2020-000777-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000777-24.